752.88 USD
-3.08 (-0.41%)
752.88 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to IDXX. IDXX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX has a decent growth rate and is not valued too expensively. These ratings would make IDXX suitable for quality investing!
1. Profitability
1.1 Basic Checks
IDXX had positive earnings in the past year.
In the past year IDXX had a positive cash flow from operations.
In the past 5 years IDXX has always been profitable.
Each year in the past 5 years IDXX had a positive operating cash flow.
1.2 Ratios
IDXX has a better Return On Assets (30.34%) than 99.47% of its industry peers.
IDXX has a better Return On Equity (65.81%) than 99.47% of its industry peers.
With an excellent Return On Invested Capital value of 40.25%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 8.71%.
The 3 year average ROIC (35.08%) for IDXX is below the current ROIC(40.25%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.25% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
1.3 Margins
Looking at the Profit Margin, with a value of 24.65%, IDXX belongs to the top of the industry, outperforming 94.68% of the companies in the same industry.
In the last couple of years the Profit Margin of IDXX has grown nicely.
With an excellent Operating Margin value of 31.34%, IDXX belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
IDXX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 61.72%, IDXX is in the better half of the industry, outperforming 61.70% of the companies in the same industry.
In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IDXX is creating value.
The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
The number of shares outstanding for IDXX has been reduced compared to 5 years ago.
Compared to 1 year ago, IDXX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 24.88 indicates that IDXX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 24.88, IDXX belongs to the top of the industry, outperforming 96.81% of the companies in the same industry.
IDXX has a debt to FCF ratio of 1.04. This is a very positive value and a sign of high solvency as it would only need 1.04 years to pay back of all of its debts.
IDXX has a Debt to FCF ratio of 1.04. This is amongst the best in the industry. IDXX outperforms 90.96% of its industry peers.
A Debt/Equity ratio of 0.53 indicates that IDXX is somewhat dependend on debt financing.
The Debt to Equity ratio of IDXX (0.53) is comparable to the rest of the industry.
Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 24.88 |
ROIC/WACC4.49
WACC8.97%
2.3 Liquidity
A Current Ratio of 1.18 indicates that IDXX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.18, IDXX is doing worse than 83.51% of the companies in the same industry.
A Quick Ratio of 0.87 indicates that IDXX may have some problems paying its short term obligations.
IDXX has a worse Quick ratio (0.87) than 82.98% of its industry peers.
The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.16% over the past year.
The Earnings Per Share has been growing by 18.18% on average over the past years. This is quite good.
The Revenue has grown by 8.39% in the past year. This is quite good.
Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
3.2 Future
Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.81% on average per year.
IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.18% yearly.
EPS Next Y14.37%
EPS Next 2Y13.33%
EPS Next 3Y13.16%
EPS Next 5Y13.81%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y9.18%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 59.70, which means the current valuation is very expensive for IDXX.
Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.09% of the companies listed in the same industry.
IDXX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.31.
The Price/Forward Earnings ratio is 52.11, which means the current valuation is very expensive for IDXX.
69.15% of the companies in the same industry are more expensive than IDXX, based on the Price/Forward Earnings ratio.
IDXX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.7 | ||
| Fwd PE | 52.11 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IDXX is valued a bit cheaper than 68.62% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than 71.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 63.94 | ||
| EV/EBITDA | 41.79 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IDXX may justify a higher PE ratio.
IDXX's earnings are expected to grow with 13.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.16
PEG (5Y)3.28
EPS Next 2Y13.33%
EPS Next 3Y13.16%
5. Dividend
5.1 Amount
IDXX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
752.88
-3.08 (-0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.04%
Inst Owner Change-0.98%
Ins Owners0.2%
Ins Owner Change2.58%
Market Cap60.12B
Revenue(TTM)4.17B
Net Income(TTM)1.03B
Analysts80
Price Target773.18 (2.7%)
Short Float %2.16%
Short Ratio3.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)11.33%
PT rev (3m)11.82%
EPS NQ rev (1m)1.27%
EPS NQ rev (3m)1.8%
EPS NY rev (1m)0%
EPS NY rev (3m)0.09%
Revenue NQ rev (1m)1.39%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.7 | ||
| Fwd PE | 52.11 | ||
| P/S | 14.43 | ||
| P/FCF | 63.94 | ||
| P/OCF | 55.25 | ||
| P/B | 38.51 | ||
| P/tB | 58.21 | ||
| EV/EBITDA | 41.79 |
EPS(TTM)12.61
EY1.67%
EPS(NY)14.45
Fwd EY1.92%
FCF(TTM)11.77
FCFY1.56%
OCF(TTM)13.63
OCFY1.81%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)4.16
PEG (5Y)3.28
Graham Number74.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.25% | ||
| ROICexc | 43.77% | ||
| ROICexgc | 56.25% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.7%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.28%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 24.88 |
F-Score8
WACC8.97%
ROIC/WACC4.49
Cap/Depr(3y)119.67%
Cap/Depr(5y)117.13%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
EPS Next Y14.37%
EPS Next 2Y13.33%
EPS Next 3Y13.16%
EPS Next 5Y13.81%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y9.18%
EBIT growth 1Y17.46%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year31.91%
EBIT Next 3Y16.8%
EBIT Next 5Y14.77%
FCF growth 1Y38.31%
FCF growth 3Y7.86%
FCF growth 5Y21.3%
OCF growth 1Y31.08%
OCF growth 3Y7.13%
OCF growth 5Y15.14%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
Can you provide the valuation status for IDEXX LABORATORIES INC?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What is the valuation of IDEXX LABORATORIES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 59.7 and the Price/Book (PB) ratio is 38.51.
Can you provide the expected EPS growth for IDXX stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 14.37% in the next year.